2022
The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review
Gottschalk C, Buse DC, Marmura MJ, Torphy B, Pavlovic JM, Dumas PK, Lalvani N, Blumenfeld A. The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. Therapeutic Advances In Neurological Disorders 2022, 15: 17562864221095902. PMID: 35662957, PMCID: PMC9160905, DOI: 10.1177/17562864221095902.Peer-Reviewed Original ResearchMigraine preventionEarly onsetDay 1Migraine daysAvailable clinical trial evidenceAnti-CGRP monoclonal antibodiesFirst treatment weekMigraine preventive therapyMigraine preventive treatmentTraditional oral agentsWeekly migraine daysClinical trial evidenceLeast moderate severityPatient-level outcomesRelevant benefitsOnset preventionOral agentsPreventive therapyChronic migraineMigraine frequencyTrial evidenceTreatment weekPreventive treatmentModerate severityPreventive benefitsThe importance of an early onset of migraine preventive disease control: A roundtable discussion
Gottschalk C, Basu A, Blumenfeld A, Torphy B, Marmura M, Pavlovic J, Dumas P, Lalvani N, Buse D. The importance of an early onset of migraine preventive disease control: A roundtable discussion. Cephalalgia Reports 2022, 5: 25158163221134593. DOI: 10.1177/25158163221134593.Peer-Reviewed Original ResearchEarly onsetDisease controlPreventive therapyMigraine activityAnti-calcitonin gene-related peptide monoclonal antibodyMigraine preventive therapyBurden of migrainePeptide monoclonal antibodyRoundtable of expertsMigraine preventionTreatment initiationPreventive benefitsClinical studiesTreatment expectationsClinical relevancePatientsDrug AdministrationPatient advocatesTherapy goalsHealthcare professionalsMonoclonal antibodiesRoundtable meetingPreventionGrey literatureProfessionals' perceptions
2019
Beta-Blockers for Migraine Prevention: a Review Article
Danesh A, Gottschalk PCH. Beta-Blockers for Migraine Prevention: a Review Article. Current Treatment Options In Neurology 2019, 21: 20. PMID: 30903383, DOI: 10.1007/s11940-019-0556-3.Peer-Reviewed Original ResearchMigraine prophylaxisMechanism of actionFavorable side effect profileBeta-blocker useCommon prophylactic agentsGroup of medicationsRecent FindingsNew evidenceClasses of medicationsSide effect profileSignificant clinical differencesMigraine preventionBeta blockersEffect profileClinical differencesProphylactic agentProphylaxisNumerous trialsRecent evidenceMedicationsPrevious reportsDosesRelative benefitsExtensive evidenceReview articleOptimum doses